Screening for Lipid Disorders
Customize your policy alerts
Sign up for Aetna Policy 0525 alerts
Get alerted when Policy 0525 changes without checking for updates manually.
Monitor payer policy activity
Defines Aetna's coverage stance for laboratory screening tests for lipid disorders (cholesterol, HDL, LDL, triglycerides, and related direct measurements) and identifies investigational tests; applies to members under Aetna plans and to ordering providers seeking coverage determinations.
No material clinical or coverage changes in this revision.
Coverage Criteria
Medically Necessary
Aetna considers the following medically necessary:
From Aetna policy medical necessity section
Experimental / Investigational
The following are considered experimental and investigational:
Listed as experimental/investigational in policy
Covered when supported by evidence
Key evidence-based conclusions and implications:
From systematic reviews and UpToDate summary
USPSTF evidence reviews and systematic trial summaries
Systematic review of cascade strategies
Cholesterol screening of asymptomatic persons is governed by member plan preventive benefits. Cholesterol screening of asymptomatic persons is not covered for members whose plans do not provide coverage for preventive services. Diagnostic cholesterol testing, however, remains covered when medically necessary regardless of whether a member’s plan covers preventive services; check benefit plan descriptions for specifics.
Evidence for universal childhood screening for familial hypercholesterolemia (FH) is limited with respect to long-term clinical outcomes. Systematic reviews found a diagnostic yield of approximately 1.3–4.8 cases per 1,000 screened, but there is no eligible evidence demonstrating that childhood screening for FH affects myocardial infarction or stroke in adulthood. Short-term trials document LDL-C reductions with lipid-lowering therapy in children, but long-term benefits and harms of initiating such therapy in childhood are not established.
Direct measurement of LDL-C and VLDL-C has specific, limited indications. Aetna considers directly measured LDL-C medically necessary for persons with triglyceride levels greater than 250 mg/dL and for persons with type 2 diabetes, and guidance suggests direct LDL is recommended when triglycerides exceed 400 mg/dL and considered in the 250–400 mg/dL range. By contrast, direct measurement of VLDL cholesterol (CPT 83719) is considered experimental/investigational and not covered.
Lipoprotein particle testing (for example, ApoB/ApoA‑I and LDL‑P/HDL‑P) has been studied for incremental risk prediction but does not demonstrate clear added prognostic value over the standard lipid panel. Systematic reviews and guideline summaries report only marginal improvements in reclassification and consistently note null findings for the c‑statistic; associations attenuate after adjustment for standard lipid measures. Therefore, routine use of lipoprotein particle testing for cardiovascular risk assessment in asymptomatic adults is not supported.
Covered Indications
Direct LDL-C measurement
Direct LDL-C measurement is covered when selection criteria are met:
Policy states direct LDL-C preferred/covered for TG >250 mg/dL and preferred assay in type 2 diabetes
NCEP guidance referenced in policy background
Serum triglyceride measurement
Serum triglyceride measurement is covered for the following purposes:
Listed as medically necessary in policy
Background guidance supports triglyceride measurement and calculated VLDL
Total cholesterol and HDL-C
Total cholesterol and HDL-C are covered for screening and diagnosis with guideline-based periodicity:
From Aetna medical necessity statements
USPSTF and UpToDate guidance cited in background
Pediatric/adolescent screening for multifactorial dyslipidemia or familial hypercholesterolemia when clinically indicated
Screening children and adolescents is covered when clinically indicated; diagnostic yield depends on age and BMI:
USPSTF evidence synthesis
USPSTF evidence synthesis
Policy and evidence-based guidance
Coding
| E78.1 | Pure hyperglyceridemia |
| E78.2 | Mixed hyperlipidemia |
| Z13.220 | Encounter for screening for lipoid disorders |
| E08.00-E13.9 | Diabetes mellitus |
Provider Actions / Notes
Coverage tied to selection criteria
Coverage for specific CPT/ICD codes is tied to the medical necessity and selection criteria in this policy. Certain codes (for example, direct LDL-C measurement CPT 83721 and lipid panel CPT 80061) are covered only when the member meets the documented clinical indications described in the policy (eg, triglycerides >250 mg/dL, type 2 diabetes, or diagnoses such as E78.1/E78.2). Verify that the ordering and diagnosis meet the policy criteria before submission.
Prior Authorization / Plan Rules
This policy provides clinical guidance; prior authorization (PA) requirements, specific PA codes, and operational PA processes are determined by the member’s benefit plan and/or administrative procedures. Providers should check payer-specific PA lists and obtain any required authorization prior to testing to avoid claim denials.
- This CPB does not itself list PA codes or replace plan-level PA rules.
- Confirm PA requirements via provider portal or plan documents before ordering.
Coverage decision note
Coverage determinations are benefit- and contract-specific. The presence of a clinical policy bulletin does not guarantee coverage for a particular member — benefits, limitations, exclusions, and plan-level preventive coverage provisions govern final decisions.
- Check the member’s benefit plan for preventive service coverage; diagnostic testing may be covered separately when medically necessary.
- Clinical policy bulletins are guidance documents and must be applied in the context of contract terms.
Documentation for cascade testing
For cascade testing programs targeting familial hypercholesterolemia (FH), index cases should have genetic confirmation or a definitive clinical diagnosis documented in the medical record before relatives are enrolled in cascade testing. Maintain records of the index case’s diagnostic evidence and the outreach/testing of relatives per program protocols.
- Document genetic confirmation or definitive clinical diagnosis for index cases before cascade testing.
- Record numbers of relatives eligible, contacted, tested, and confirmed to have FH as recommended in studies and guidelines.
Therapy context
Treatment context: There are evidence summaries supporting therapy for identified lipid disorders (eg, statins, bile acid sequestrants, ezetimibe) but no step-therapy rules are specified in this policy. Providers should follow current clinical guidelines for treatment once diagnosis is established; this policy does not impose step therapy requirements.
- Evidence shows LDL-C reductions with statins and other agents in trials referenced in the background.
- No step-therapy or sequencing mandates are included in this CPB; follow applicable plan or guideline requirements for therapeutic management.
Ordering Requirements
ORDERING: select correct codes and document medical necessity
Ordering clinicians must select the appropriate CPT and ICD-10 codes and document medical necessity when requesting lipid testing; diagnostic testing requires supporting documentation.
ORDERING for cascade testing: require confirmed index case
Before initiating cascade testing of relatives, confirm that the index case has FH genetically confirmed or a definitive clinical diagnosis and document this in the clinical record.
- Do not proceed with relative cascade testing without documented genetic confirmation or definitive clinical diagnosis of the index case.
- Record the index case confirmation method and maintain documentation for program evaluation (numbers eligible, contacted, tested, confirmed).
Not Covered / Experimental
Breath isoprene measurement and cholesterol skin testing remain investigational. Breath isoprene analysis is under development, has unresolved technical and standardization issues, and has not been adopted as a routine clinical method. For these reasons, breath isoprene measurements and cholesterol skin testing are considered experimental/investigational and are not covered for screening or monitoring of lipid disorders.
Direct measurement of very low‑density lipoprotein (VLDL) cholesterol using CPT 83719 is specifically addressed in the coding and policy sections and is considered experimental/investigational and not covered.
Routine ordering of LDL particle or subfraction testing as an alternative to the standard lipid panel is not supported by the evidence cited in this policy. Studies show limited incremental predictive value beyond standard lipid measures, with no consistent improvement in c‑statistics; consequently, routine LDL particle/subfraction testing is not covered as a substitute for standard lipid panels.
Frequency Limits
Definitions
Background
Serum cholesterol levels correlate with future cardiovascular risk, and multiple guideline bodies provide varying age‑ and risk‑based screening recommendations. For average‑risk adults, guideline summaries generally recommend lipid screening at intervals of about every 5 years. Additionally, clinical guidance notes repeating lipid measurements every 3–5 years depending on proximity to treatment thresholds and prior values.
Revision History
Policy was last reviewed on 07/14/2023.
Policy effective date established as 06/15/2001.
Next scheduled policy review set for 05/23/2024.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.